To develop an HIV cure, most clinical studies involve an analytical treatment interruption (ATI)—a study participant who is living with HIV voluntarily temporarily stops taking their antiretroviral treatment (ART) regimen. Currently, this is the only way to determine if a potential cure strategy will work without ART.
Thomas J. Villa works to help end the HIV epidemic as a writer, Community Advisor to and serial participant in HIV clinical research. Tom is an Ambassador for the HOPE Martin Delaney Collaboratory for HIV Cure Research, a Community Advisor to the RID Martin Delaney Collaboratory, and a contributor to the AIDS Clinical Trials Group (ACTG) Partner Protection Working Group.
ACTIVELY INVOLVEMENT: THOMAS J. VILLA
Mexico – Matthew Bendall, Bhavya Singh and Jez Marston presented HOPE related studies at the Fusion Conference: Probing Human Disease Using Single-Cell Technologies, in Mexico in May 2022. Their poster entitled “Single cell retrotranscriptomics with Stellarscope: Developing a single cell transposable element atlas of human cell identity” won the best poster award. Congratulations to all of the authors!
New York, NY – The 2021 Telescope “dark matter” codeathon, hosted by the Nixon Lab at WCM, brought together an international team of biologists, computational scientists, and bioinformaticians for an intense week of coding, analysis, and writing. The goal of this codeathon was to develop a robust, open source software pipeline for analyzing transposable element expression in single cell RNA-seq data.